Updated: Sep 16, 2019
Bridge Point Capital, a private equity firm based in New York City that specializes in U.S/China cross-border healthcare investments, is pleased to announce that Shirley Zhao, former General Manager & President of China Mainland & HK of Bristol-Myers Squibb, will join the firm’s Advisory Board by the end of September.
Shirley Zhao was the general manager & president of China mainland & HK of Bristol-Myers Squibb. She has 26 years’ experience of working in large cross border pharmaceuticals including Vice President and Country President at Allergan, Managing Director at Genzyme, Commercial Director at Baxter of Japan, China and North Asia and Vice President at Eli Lilly China led the Oncology Business. She also serves as the Board of Governor at AmCham Shanghai in 2015.
As an outstanding manager, Ms. Shirley Zhao’s high level of integrity as the core of all decision-making and strong skills in market access, fostering entrepreneurial culture and utilizing public relations guaranteed her business success. Outperformed the market during times of rapid growth and met revenue and profit targets during more difficult times, she helped the companies she worked for to overcome most of the barriers in China market.
Shirley Zhao will boost the marketing ability of Bridge Point Capital on China side. At the same time, her excellent insights and deep knowledge in the healthcare industry will help Bridge Point Capital deploy capital more efficiently and bring more profit for our investors.
Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast, yet unexplored, Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to provide the best investment platform we possibly can for our investors.